Financing drug development via adaptive platform trials

Area of Science:

• Biomedical Research
• Health Economics
• Clinical Trial Design

Background:

• Traditional drug development funding is lengthy and capital-intensive.
• Adaptive platform trials offer efficiency but require innovative financial models.

Purpose of the Study:

• To propose a new funding mechanism for disease-specific drug development.
• To evaluate the financial viability and return potential for investors in this model.

Main Methods:

• Utilizing a variation of the adaptive platform trial design.
• Modeling investor returns based on realistic cost, revenue, success probability, sales, and royalty rates.
• Analyzing return distributions for different investor types.

Main Results:

• Investors may expect a 28% return, with a 22% risk of total loss.
• The model shows potential attractiveness for hedge funds, family offices, and philanthropic investors.
• Securitizing aggregate cash flows from multiple trials may appeal to mainstream investors.

Conclusions:

• This novel funding approach integrates investment with adaptive platform trials for drug development.
• The financial projections suggest a viable model for attracting diverse investment, balancing social impact and financial returns.
• Further securitization strategies can broaden investor appeal for mainstream markets.